Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system

Journal of Neuroimmunology

Volumn 126, Issue 1-2, 2002, Pages 58-68

  Aharoni, Rina ^a   Meshorer, Asher ^a   Sela, Michael ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmunity; Central nervous system (CNS); Copolymer 1 (Cop 1, Copaxone , glatiramer acetate); Experimental autoimmune encephalomyelitis (EAE); Multiple sclerosis (MS); T helper type 2 (Th2) cytokines

Indexed keywords

GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MYELIN BASIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CELL SECRETION; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE RELEASE; FEEDING; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; SUPPRESSOR CELL; TH1 CELL; TH2 CELL;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; BRAIN; CROSS REACTIONS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-12; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MULTIPLE SCLEROSIS; MURAMIDASE; PEPTIDES; TH2 CELLS;

EID: 0036098325     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00053-X     Document Type: Article

References (28)

1. T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis
2. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis
3. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1
4. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1
5. Antigen-driven peripheral immune tolerance: Suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen
6. Chronologic localization of myelin-reactive cells in the lesion of relapsing EAE: Implications for the study of multiple sclerosis
7. Glatiramer acetate (Copaxone) induces degenerate Th2-polarized immune response in patients with multiple sclerosis
8. Oral tolerance: Mechanisms and therapeutic applications
9. Treatment of multiple sclerosis with Copaxone (Cop): Elispot assay detected Cop 1 induced interlukin-4 and interferon-g response in blood cells
10. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis
11. Antigen-specific immunosuppression: Oral tolerance for the treatment of autoimmune disease
12. Basic encephalitogenic protein: A simplified purification on sulfoethyl Sephadex
13. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
14. Extended use of Glatiramer Acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
15. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlated with recovery
16. The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis
17. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient host rather than protect them from the disease
18. The fate of T cells in the brain veni, vidi, vici and veni, mori
19. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases
20. Treatment of multiple sclerosis with copolymer 1: (Copaxone) implicating mechanism of Th1 to Th2/Th3 immune deviation
21. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation
22. Multiple sclerosis: Comparison of copolymer 1-reactive T-cell lines from treated and untreated subjects reveals cytokine shift from Th1 to Th2
23. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
24. Development of Copolymer 1 (Copaxone) as a specific drug against multiple sclerosis
25. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of Copolymer 1
26. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
27. Cellular immune reactivity within the CNS